Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1
Abstract Drug resistance remains a significant challenge in the treatment of pancreatic cancer. The development of drug-resistant cell lines is crucial to understanding the underlying mechanisms of resistance and developing novel drugs to improve clinical outcomes. Here, a novel pancreatic cancer ce...
| Glavni autori: | , , , , , , , , , , , , , |
|---|---|
| Format: | Članak |
| Jezik: | English |
| Izdano: |
BMC
2024-07-01
|
| Serija: | BMC Cancer |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s12885-024-12588-w |
| _version_ | 1827195963393966080 |
|---|---|
| author | Cheng Yu Yuanhui Su Xin Miao Changpeng Chai Huan Tang Lu Li Jianfeng Yi Zhenzhen Ye Hui Zhang Zhao Hu Luyang Chen Ning Li Hao Xu Wence Zhou |
| author_facet | Cheng Yu Yuanhui Su Xin Miao Changpeng Chai Huan Tang Lu Li Jianfeng Yi Zhenzhen Ye Hui Zhang Zhao Hu Luyang Chen Ning Li Hao Xu Wence Zhou |
| author_sort | Cheng Yu |
| collection | DOAJ |
| description | Abstract Drug resistance remains a significant challenge in the treatment of pancreatic cancer. The development of drug-resistant cell lines is crucial to understanding the underlying mechanisms of resistance and developing novel drugs to improve clinical outcomes. Here, a novel pancreatic cancer cell line, PDAC-X1, derived from Chinese patients has been established. PDAC-X1 was characterized by the immune phenotype, biology, genetics, molecular characteristics, and tumorigenicity. In vitro analysis revealed that PDAC-X1 cells exhibited epithelial morphology and cell markers (CK7 and CK19), expressed cancer-associated markers (E-cadherin, Vimentin, Ki-67, CEA, CA19-9), and produced pancreatic cancer-like organs in suspension culture. In vivo analysis showed that PDAC-X1 cells maintained tumorigenicity with a 100% tumor formation rate. This cell line exhibited a complex karyotype, dominated by subtriploid karyotypes. In addition, PDAC-X1 cells exhibited intrinsic multidrug resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil, and oxaliplatin. In conclusion, the PDAC-X1 cell line has been established and characterized, representing a useful and valuable preclinical model to study the underlying mechanisms of drug resistance and develop novel drug therapeutics to improve patient outcomes. |
| first_indexed | 2025-03-21T09:37:41Z |
| format | Article |
| id | doaj.art-3405ce25d38b4c0c83a7eb63c6a6e4c2 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2025-03-21T09:37:41Z |
| publishDate | 2024-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-3405ce25d38b4c0c83a7eb63c6a6e4c22024-07-07T11:25:53ZengBMCBMC Cancer1471-24072024-07-0124111310.1186/s12885-024-12588-wEstablishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1Cheng Yu0Yuanhui Su1Xin Miao2Changpeng Chai3Huan Tang4Lu Li5Jianfeng Yi6Zhenzhen Ye7Hui Zhang8Zhao Hu9Luyang Chen10Ning Li11Hao Xu12Wence Zhou13The Second Clinical Medical School, Lanzhou UniversityThe Second Clinical Medical School, Lanzhou UniversityThe First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Zhejiang Chinese Medical UniversityThe Second Clinical Medical School, Lanzhou UniversityThe Second Clinical Medical School, Lanzhou UniversityThe Fourth Department of General Surgery, The First Hospital of Lanzhou UniversityThe First Clinical Medical School, Lanzhou UniversityThe Second Clinical Medical School, Lanzhou UniversityThe Second Clinical Medical School, Lanzhou UniversityThe First School of Clinical Medicine, Zhejiang Chinese Medical UniversityThe First School of Clinical Medicine, Zhejiang Chinese Medical UniversityThe First School of Clinical Medicine, Zhejiang Chinese Medical UniversityThe First School of Clinical Medicine, Zhejiang Chinese Medical UniversityThe Second Clinical Medical School, Lanzhou UniversityAbstract Drug resistance remains a significant challenge in the treatment of pancreatic cancer. The development of drug-resistant cell lines is crucial to understanding the underlying mechanisms of resistance and developing novel drugs to improve clinical outcomes. Here, a novel pancreatic cancer cell line, PDAC-X1, derived from Chinese patients has been established. PDAC-X1 was characterized by the immune phenotype, biology, genetics, molecular characteristics, and tumorigenicity. In vitro analysis revealed that PDAC-X1 cells exhibited epithelial morphology and cell markers (CK7 and CK19), expressed cancer-associated markers (E-cadherin, Vimentin, Ki-67, CEA, CA19-9), and produced pancreatic cancer-like organs in suspension culture. In vivo analysis showed that PDAC-X1 cells maintained tumorigenicity with a 100% tumor formation rate. This cell line exhibited a complex karyotype, dominated by subtriploid karyotypes. In addition, PDAC-X1 cells exhibited intrinsic multidrug resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil, and oxaliplatin. In conclusion, the PDAC-X1 cell line has been established and characterized, representing a useful and valuable preclinical model to study the underlying mechanisms of drug resistance and develop novel drug therapeutics to improve patient outcomes.https://doi.org/10.1186/s12885-024-12588-wPancreatic cancerTumor cell lineChemotherapyIntrinsic multidrug resistanceTransplanted tumor |
| spellingShingle | Cheng Yu Yuanhui Su Xin Miao Changpeng Chai Huan Tang Lu Li Jianfeng Yi Zhenzhen Ye Hui Zhang Zhao Hu Luyang Chen Ning Li Hao Xu Wence Zhou Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1 BMC Cancer Pancreatic cancer Tumor cell line Chemotherapy Intrinsic multidrug resistance Transplanted tumor |
| title | Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1 |
| title_full | Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1 |
| title_fullStr | Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1 |
| title_full_unstemmed | Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1 |
| title_short | Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1 |
| title_sort | establishment and characterization of a novel multidrug resistant pancreatic ductal adenocarcinoma cell line pdac x1 |
| topic | Pancreatic cancer Tumor cell line Chemotherapy Intrinsic multidrug resistance Transplanted tumor |
| url | https://doi.org/10.1186/s12885-024-12588-w |
| work_keys_str_mv | AT chengyu establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT yuanhuisu establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT xinmiao establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT changpengchai establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT huantang establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT luli establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT jianfengyi establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT zhenzhenye establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT huizhang establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT zhaohu establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT luyangchen establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT ningli establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT haoxu establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 AT wencezhou establishmentandcharacterizationofanovelmultidrugresistantpancreaticductaladenocarcinomacelllinepdacx1 |